A Medical Device Daily

Double Helix Group (London) has launched a U.S. division, Double Helix Consulting US (DHC US; New York), headed by Andrew Baker.

"The establishment of Double Helix Consultants US is a further extension of our core business and continues our overall expansion and development program for 2009 and beyond," said Wayne Phillips, CEO of Double Helix Group.

According to the company, the new venture consists of a multidisciplinary team of strategic pricing, reimbursement and market access consultants with experience across the healthcare industry as well as commercial, government and academic links, who provide customer-centric market access strategies to clients in the pharmaceutical, biotech, and medical device industries. DHC US provides services spanning the product lifecycle.

Those services include product value message development and testing; commercial assessment; lifecycle planning; development program and clinical trial planning; managed markets strategy; pharmacoeconomic evaluation and health technology assessment; payer and provider insight evaluation and influence planning; pricing and reimbursement strategy, negotiation simulation, and training; environmental scenario planning on key issues such as HTA decision intelligence, formulary design, utilization management strategies, policy reform, value-based benefit design, pay-for-performance, and healthcare quality measurement and accreditation; and market access training.

"Double Helix Consulting US offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client – and consulting sides. As an example, our growing emerging markets practice provides clients with the intelligence to implement successful strategies in the world's largest and most rapidly developing economies," Baker said.